Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.

San Donato Group (GSD)

Status: Enrolling

Conditions: Acromegaly

Treatments: Procedure: Blood sample; Other: Questionnaires; Diagnostic Test: Radiological tests

Study type: Observational

Funder types: Other

Identifiers

NCT06344650

RF-2021-12373584

Details and patient eligibility

About

Prospective observational clinical, molecular, translational study aimed at identifying the main determinants and predictive factors of fragility fracture risck in acromegaly patients

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• confirmed diagnosis of acromegaly
• availability to carry out outpatient checks
• ability to provide informed consent

Exclusion criteria

• Pregnancy
• use of glucocorticoids (except those in use for replacement therapy)
• alcohol abuse
• exacerbation of chronic disease
• serious comorbidities (renal or hepatic failure, heart attack, stroke)
• terminally ill, prolonged immobilization (>1 week)
• clinically evident fracture within the previous six months
• any other cause of secondary osteoporosis within the last five years
• any prolonged treatment with drugs with documented influence on bone metabolism during the previous 12 months, including treatment with antiresorptive or anabolic compounds for osteoporosis.